A review of epidemiologic studies of nonnarcotic analgesics and chronic renal disease

Medicine

Volumn 77, Issue 2, 1998, Pages 102-121

  Delzell, Elizabeth ^a   Shapiro, Samuel ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPHENOL; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTHRANILIC ACID DERIVATIVE; CAFFEINE; INDOLEACETIC ACID DERIVATIVE; KETOROLAC TROMETAMOL; LEVOMEPROMAZINE; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PARACETAMOL; PHENACETIN; PROPIONIC ACID DERIVATIVE; PYRAZOLONE DERIVATIVE; SALICYLAMIDE; SALICYLIC ACID DERIVATIVE; TRAMADOL;

ANALGESIC NEPHROPATHY; ARTICLE; CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; DRUG CLASSIFICATION; EPIDEMIOLOGY; FOLLOW UP; HUMAN; KIDNEY PAPILLA NECROSIS; NEPHROTOXICITY; PRIORITY JOURNAL; URINALYSIS;

ADULT; AGED; ANALGESICS; BELGIUM; BIAS (EPIDEMIOLOGY); CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDEMIOLOGIC METHODS; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RISK ASSESSMENT; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 0031960115     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-199803000-00003     Document Type: Article

References (108)

1. Abel JA. Analgesic nephropathy - a review of the literature, 1967-1970. Clin Pharmacol Ther 12: 583-98, 1971.
2. Arnold L, Collins C, Starmer GA. Analgesic abuse, renal papillary necrosis and concomitant drug intake. Aust N Z J Med 7: 253-58, 1977.
3. Bach PH, Bridges JW. Chemically induced renal papillary necrosis and upper urothelial carcinoma. Parts 1 and 2. CRC Crit R Toxicol 15: 217-439, 1985.
4. Bach PH, Hardy TL. Relevance of animal models to analgesic-associated renal papillary necrosis in humans. Kidney Int 28: 605-13, 1985.
5. Bengtsson U. Prevention of renal disease. Proc Eur Dial Transplant Assoc 16: 466-74, 1979.
6. Bennett WM, Elzinga LW, Porter GA. Tubulointerstitial disease and toxic nephropathy. In: Brenner BM, Rector FC, eds. The kidney. Philadelphia: WB Saunders, pp 1430-96, 1991.
7. Bishop J, Znamirowska MI, Meltzer AS. Regulations controlling the sale of mild analgesics in Canada. Can Med Assoc J 107: 758-68, 1972.
8. Brezis M, Rosen S. Hypoxia of the renal medulla - its implications for disease. N Engl J Med 332: 647-55, 1995.
9. Brunner FP, Selwood NH. End stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. Nephrol Dial Transplant 9: 1371-76, 1994.
10. Buckalew VM, Schey HM. Analgesic nephropathy: A significant cause of morbidity in the United States. Am J Kidney Dis 7: 164-68, 1986.
11. Buckalew VM, Schey HM. Renal disease from habitual antipyretic analgesic consumption: An assessment of the epidemiologic evidence. Medicine (Baltimore) 65: 291-303, 1986.
12. Bulger RJ, Healey LA, Polinsky P. Renal abnormalities in rheumatoid arthritis. Ann Rheum Dis 27: 339-43, 1968.
13. Burry A, Hopkins J. Phenacetin and analgesic nephropathy. Med J Aust 1: 879-82, 1977.
14. Burry AF, Axelsen RA, Trolove P. Analgesic nephropathy: Its present contribution to renal mortality and morbidity profile. Med J Aust 1: 31-36, 1974.
15. Burry AF, De Jersey P, Weedon D. Phenacetin and renal papillary necrosis: Results of a prospective autopsy investigation. Med J Aust 1: 873-79, 1966.
16. Burry HC, Dieppe PA, Bresnihan FB, et al. Salicylates and renal function in rheumatoid arthritis. Br Med J 1: 613-15, 1976.
17. Chow WH, McLaughlin JK, Linet MS, et al. Use of analgesics and risk of renal cell cancer. Int J Cancer 59: 467-70, 1994.
18. Chrischilles EA, Foley DJ, Wallace RB, et al. Use of medications by persons 65 and over: Data from the established populations for epidemiologic studies of the elderly. J Gerontol 47: 137-44, 1992.
19. Christie D, McPherson L, Kincaid-Smith P. Analgesics and the kidney: A community based study. Med J Aust 2: 527-29, 1976.
20. Clausen E, Pedersen J. Necrosis of renal papillae in rheumatoid arthritis. Acta Med Scand 170: 631-33, 1961.
21. Dawborn JK, Fairley KF, Kincaid-Smith P, King WE. The association of peptic ulceration, chronic renal disease, and analgesic abuse. Q J Med 35: 69-83, 1966.
22. De Broe ME, Elseviers MM. Analgesic nephropathy - still a problem? Nephron 64: 505-13, 1993.
23. Derby LE, Jick H. Renal parenchymal disease related to over-the-counter analgesic use. Pharmacotherapy 11: 467-71, 1991.
24. Disney AP. Demography and survival of patients receiving treatment for chronic renal failure in Australia and New Zealand; report on dialysis and renal transplantation treatment from the Australia and New Zealand Dialysis and Transplant Registry. Am J Kidney Dis 25: 165-75, 1995.
25. Disney APS, Correll RL. Report of the Australian and New Zealand combined dialysis and transplant registry. Med J Aust 1: 117-22, 1981.
26. Disney APS, Row PG, Subcommittee of the Australian Kidney Foundation. Australian maintenance dialysis survey. Med J Aust 2: 651-56, 1974.
27. Drukker W, Schwarz A, Vanherweghem JL. Analgesic nephropathy: An underestimated cause of end stage renal disease. Int J Artif Organs 9: 219-46, 1986.
28. Dubach UC, Levy PS, Minder F. Epidemiological study of analgesic intake and its relationship to urinary tract disorders in Switzerland. Helv Med Acta 34: 297-312, 1968.
29. Dubach UC, Levy PS, Mulle A. Relationships between regular analgesic intake and urorenal disorders in a working female population. Am J Epidemiol 93: 425-34, 1971.
30. Dubach UC, Levy PS, Rosner B, et al. Relation between regular intake of phenacetin containing analgesics and laboratory evidence for urorenal disorders in a working female population of Switzerland. Lancet 1: 539-43, 1975.
31. Dubach UC, Levy PS, Rosner B, et al. Chronic renal disease [letter]. Lancet 2: 990, 1975.
32. Dubach UC, Rosner B, Levy PS, et al. Epidemiological study in Switzerland. Kidney Int 13: 41-49, 1978.
33. Dubach UC, Rosner B, Poster E. Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968-1979). N Engl J Med 308: 357-62, 1983.
34. Dubach UC, Rosner B, Sturmer T. An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987). N Engl J Med 324: 155-60, 1991.
35. Elseviers MM, Bosteels V, Cambier P, et al. Diagnostic criteria of analgesic nephropathy in patients with end-stage renal failure: Results of the Belgian study. Nephrol Dial Transplant 7: 479-86, 1992.
36. Elseviers MM, De Broe ME. Analgesic nephropathy in Belgium is related to the sales of particular analgesic mixtures. Nephrol Dial Transplant 9: 41-46, 1994.
37. Elseviers MM, De Broe ME. Combination analgesic involvement in the pathogenesis of analgesic nephropathy: The European perspective. Am J Kidney Dis 28: S48-S55, 1996.
38. Elseviers MM, De Broe ME. Diagnostic criteria of analgesic nephropathy in patients with end-stage renal failure. Ren Fail 15: 435-37, 1993.
39. Elseviers MM, De Broe ME. A long-term prospective controlled study of analgesic abuse in Belgium. Kidney Int 48: 1912-19, 1995.
40. Elseviers MM, De Broe ME. Is analgesic nephropathy still a problem in Belgium? Nephrol Dial Transplant 2: 143-49, 1988.
41. Elseviers MM, De Schepper A, Corthouts R, et al. High diagnostic performance of CT scan for analgesic nephropathy in patients with incipient to severe renal failure. Kidney Int 48: 1316-23, 1995.
42. Elseviers MM, Waller I, Nenov D, et al. Evaluation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure. Nephrol Dial Transplant 10: 808-14, 1995.
43. Fenton S, Desmeules M, Copleston P, et al. Renal replacement therapy in Canada: A report from the Canadian Organ Replacement Register. Am J Kidney Dis 25: 134-50, 1995.
44. Ferguson I, Johnson F, Reay B, et al. Aspirin, phenacetin, and the kidney - a rheumatism clinic study. Med J Aust 1: 950-54, 1977.
45. Gault MH, Rudwal TC, Redmond NI. Analgesic habits of 500 veterans: Incidence and complications of abuse. Can Med Assoc J 98: 619-26, 1968.
46. Gilman A. Analgesic nephrotoxicity: A pharmacological analysis [editorial]. Am J Med 36: 167-73, 1964.
47. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 333: 609-14, 1995.
48. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk of colorectal cancer and adenoma in male health professionals. Ann Intern Med 121: 241-46, 1994.
49. Goldberg M. Analgesic-associated nephropathy: An important cause of chronic renal failure in the United States. Am J Kidney Dis 7: 162-63, 1986.
50. Gonwa TA, Hamilton RW, Buckalew VM. Chronic renal failure and end stage renal disease in northwest North Carolina. Arch Intern Med 141: 462-65, 1981.
51. Gregg NJ, Elseviers MM, De Broe ME, et al. Epidemiology and mechanistic basis of analgesic-associated nephropathy. Toxicol Lett 46: 141-51, 1989.
52. Grimlund K. Phenacetin and renal damage at a Swedish factory. Acta Med Scand 175(Suppl 406): 1-26, 1964.
53. Hauser AC, Derfler K, Balcke P. Progression of renal insufficiency in analgesic nephropathy: Impact of continuous drug abuse. J Clin Epidemiol 44: 53-56, 1991.
54. Henrich WL, Agodoa LE, Barrett B, et al. Analgesics and the kidney: Summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 27: 162-65, 1996.
55. Hood B, Falkheden T, Carlsson M. Trends and present pattern of mortality in chrome uremia. Acta Med Scand 181: 561-69, 1967.
56. International Agency for Research on Cancer (IARC). Overall evaluations of carcinogenicity: An updating of IARC Monographs volumes 1 to 42. IARC monographs on the evaluation of carcinogenic risks to humans, Suppl. 7. Lyons, France: WHO, pp 310-11, 1987.
57. Kasanen A. The effects of the restriction of the sale of phenacetin on the incidence of papillary necrosis established at autopsy. Ann Clin Res 5: 369-74, 1973.
58. Kerr DNS, Ward MK. Renal disorders. In: Davies DM, ed. Textbook of adverse drug reactions. 2nd ed. Oxford: Oxford University Press, pp 256-300, 1981.
59. Kincaid Smith P. Analgesic nephropathy. Aust N Z J Med 18: 251-54, 1988.
60. Kjaerulff J, Harvald B. Incidence of papillitis necroticans. Nord Med 80: 1588-90, 1968.
61. Kleinknecht D. Interstitial nephritis, the nephrotic syndrome, and chronic renal failure secondary to nonsteroidal anti-inflammatory drugs. Semin Nephrol 15: 228-35, 1995.
62. Lawson AAH, Maclean N. Renal disease and drug therapy in rhematoid arthritis. Ann Rheum Dis 25: 441-49, 1966.
63. Lawson DH. Analgesic consumption and impaired renal function. J Chron Dis 26: 39-45, 1973.
64. Linet MS, Chow WH, McLaugnlin JK, et al. Analgesics and cancers of the renal pelvis and ureter. Int J Cancer 62: 5-18, 1995.
65. Mabeck CE, Wichmann B. Mortality from chronic interstitial nephritis and phenacetin consumption in Denmark. Acta Med Scan 205: 599-601, 1979.
66. Macklon AF, Craft AW, Thompson M, et al. Aspirin and analgesic nephropathy. Br Med J 1: 597-600, 1974.
67. McAnally JF, Winchester JF, Schreiner GE. Analgesic nephropathy. An uncommon cause of end stage disease. Arch Intern Med 143: 1897-99, 1983.
68. McCredie M, Disney APS, Coates MS, et al. Geographical distribution of cancers of the kidney and urinary tract and analgesic nephropathy in Australia and New Zealand. Aust N Z J Med 20: 684-94, 1990.
69. McCredie M, Stewart JH, Mahony JF. Is phenacetin responsible for analgesic nephropathy in New South Wales? Clin Nephrol 17: 134-40, 1982.
70. McCredie M, Stewart JH, Mathew TH, et al. The effect of withdrawal of phenacetin-containing analgesics on the incidence of kidney and urothelial cancer and renal failure. Clin Nephrol 31: 35-39, 1989.
71. McCredie M, Stewart JH. Does paracetamol cause urothelial cancer or renal papillary necrosis? Nephron 49: 296-300, 1988.
72. Michielsen P, De Schepper P. Analgesic nephropathy. Are new legal regulations needed? Tijdschr voor Geneeskunde 52: 1-9, 1996.
73. Morlans M, LaPorte J, Vidal X, et al. End-stage renal disease and non-narcotic analgesics: A case-control study. Br J Clin Pharmacol 30: 717-23, 1990.
74. Murray TG, Stolley PD, Anthony JC, et al. Epidemiologic study of regular analgesic use and end-stage renal disease. Arch Intern Med 143: 1687-93, 1983.
75. Nanra RS, Kincaid Smith P. Renal papillary necrosis in rheumatoid arthritis. Med J Aust 1: 194-97, 1975.
76. Nanra RS, Kincaid Smith P. Experimental evidence for nephrotoxicity of analgesics. In: Stewart JH, ed. Analgesic and NSAID-induced kidney disease. Oxford: Oxford University Press, pp 17-31, 1993.
77. New Zealand Rheumatism Association Study. Aspirin and the kidney. Br Med J 1: 593-96, 1974.
78. Noels LM, Elseviers MM, De Broe ME. Impact of legislative measures on the sales of analgesics and the subsequent prevalence of analgesic nephropathy: A comparative study in France, Sweden and Belgium. Nephrol Dial Transplant 10: 167-74, 1995.
79. Nordenfelt O. Deaths from renal failure in abusers of phenacetin-containing drugs. Acta Med Scand 191: 11-16, 1972.
80. Perneger TV, Whelton PK, Klag MJ. Kidney failure and analgesic drugs [letter]. N Engl J Med 332: 1515-16, 1995.
81. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 331: 1675-70, 1994.
82. Pommer W, Bronder E, Greiser E, et al. Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 9: 403-12, 1989.
83. Pommer W, Glaeske G, Molzahn M. The analgesic problem in the Federal Republic of Germany: Analgesic consumption, frequency of analgesic nephropathy and regional differences. Clin Nephrol 26: 273-78, 1986.
84. Prescott LF. Analgesic nephropathy: A reassessment of the role of phenacetin and other analgesics. Drugs 23: 75-149, 1982.
85. Sabatini S. Analgesic-induced papillary necrosis. Semin Nephrol 8: 41-54, 1988.
86. Sabatini S. Pathophysiologic mechanisms in analgesic-induced papillary necrosis. Am J Kidney Dis 28: S34-S38, 1996.
87. Sandler DP. Non-aspirin nonsteroidal anti-inflammatory drug use and chronic renal disease risk. In: Bach PH, ed. Nephrotoxicity. New York: Marcel Dekker, pp 73-77, 1991.
88. Sandler DP, Burr R, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 115: 165-72, 1991.
89. Sandler DP, Smith JC, Weinberg CR, et al. Analgesic use and chronic renal disease. N Engl J Med 320: 1238-43, 1989.
90. Sandler DP, Weinberg CR. Analgesic use and chronic renal disease [letter]. N Engl J Med 321: 1126-27, 1989.
91. Schwarz A. Analgesic-associated nephropathy. Klin Wochenschr 65: 1-16, 1987.
92. Schwarz A, Kunzendorf U, Keller F, et al. Progression of renal failure in analgesic-associated nephropathy. Nephron 53: 244-49, 1989.
93. Segasothy M, Abdul Samad S, Zulfiqar A, et al. Computed tomography and ultrasonography: A comparative study in the diagnosis of analgesic nephropathy. Nephron 66: 62-66, 1994.
94. Segasothy M, Samad SA, Sulfigar A, Bennett WM. Chronic renal disease and papillary necrosis associated with long-term use of nonsteroidal anti-inflammatory drags as the sole or predominant analgesic. Am J Kidney Dis 24: 17-24, 1994.
95. Shapiro S, Castellana JV, Sprafka JM. Alcohol-containing mouthwashes and oropharyngeal cancer: A spurious association due to underascertainment of confounders? Am J Epidemiol 144: 1091-95, 1996.
96. Shelley JH. Phenacetin, through the looking glass. Clin Pharmacol Ther 8: 427-71, 1967.
97. Sillanpaa M, Kasanen A, Elonen A. Changes of panorama in renal disease mortality in Finland after phenacetin restriction. Acta Med Scand 212: 313-17, 1982.
98. Sorensen AWS. Is the relation between analgesics and renal disease coincidental and not causal? Nephron 3: 366-76, 1966.
99. Spühler O, Zollinger HU. Die chronisch-interstitielle nephritis. Z Klin Med 151: 1-50, 1953.
100. Steenland NK, Thun MJ, Ferguson CW, et al. Occupational and other exposures associated with male end-stage renal disease: A case-control study. Am J Public Health 80: 153-57, 1990.
101. Stewart JH. Analgesic abuse and renal failure in Australasia. Kidney Int 13: 72-78, 1978.
102. Thun MJ, Namboodiri MM, Calle EE, et al. Aspirin use and risk of fatal cancer. Cancer Res 53: 1322-27, 1993.
103. United States Renal Data System: 1996 Annual data report. III. Incidence and causes of treated ESRD. Am J Kidney Dis 26: S39-S50, 1996.
104. Vanherweghem JL, Even Adin D. Epidemiology of analgesic nephropathy in Belgium. Clin Nephrol 17: 129-33, 1982.
105. Vans J, Oksa H, Pasternack A. Hospitalization for renal diseases in Finland 1969-1982. Scand J Urol Nephrol 22: 197-205, 1988.
106. Waters WE, Elwood PC, Asscher AW. Community survey of analgesic consumption and kidney function in women. Lancet 1: 341-44, 1973.
107. Wilson DR, Gault MH. Declining incidence of analgesic nephropathy in Canada. Can Med Assoc J 127: 500-502, 1982.
108. Wing AJ, Brunner FP, Geerlings W, et al. Contribution of toxic nephropathies to end-stage renal failure in Europe: A report from the EDTA-ERA registry. Toxicol Lett 46: 281-92, 1989.